Mesh Bio: The role of deep tech in modern healthcare
What if we can prevent catastrophic diseases such as diabetes, kidney failure, and stroke with deep tech? The word deep tech might still be unfamiliar to people’s ears as it first emerged in 2014.
Investing in healthtech to tackle Indonesia’s greatest challenges
The COVID-19 pandemic has exposed critical gaps in Indonesia’s healthcare infrastructure, revealing structural and systemic shortcomings that will require scalable solutions. Change doesn't happen overnight, particularly for the healthcare sector, which consists of multiple intertwined industries with strict regulatory oversight. But precisely because the industry is highly regulated, regulations play a huge role in shaping trends.
Mesh Bio raises US$3.5 million of Series A funding led by East Ventures, to make its digital twin technologies available at scale
Mesh Bio, a Singapore-based health deep tech startup transforming chronic disease management through predictive analytics, announced today that it has raised US$3.5 million in Series A financing led by East Ventures, a pioneering and leading sector-agnostic venture capital firm focusing on Southeast Asia. This round of investment is also participated by Elev8, Seed Capitals, and other existing shareholders.
Mesh Bio, a health deep tech startup, secured investment from East Ventures
Mesh Bio, a Singapore-based health deep tech startup in transforming chronic disease management through predictive analytics, announced that it had raised an undisclosed amount of funding from East Ventures, a pioneering and leading sector-agnostic venture capital firm focusing on Southeast Asia. The funding will be allocated to further develop the digital twin technologies in chronic disease management and to expand its services across Southeast Asia, mainly Indonesia, Malaysia, and the Philippines.